On the stock market since 2013, it operates in the world of health and science. It has 25,258 employees. Now — the numbers.
This is an established company with proven profits.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
Average growth of 11% a year over the last 4 years. Every year shown ended in profit.
The gap is $8.8B. In times of high interest rates, a gap like that can squeeze a company.
The stock trades 44% below its peak. The market has trimmed its expectations for the company.
It pays out $0.28 per share each year — regular cash for whoever holds the stock.
The weight of investors positioned for a fall can be felt in the market.
On our five-subject report card, GIFOF sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: GIFOF is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.